已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Vaccinating patients on biologics for atopic disease: Clinical considerations and evidence-based recommendations

医学 接种疫苗 观察研究 随机对照试验 重症监护医学 临床试验 安慰剂 免疫学 不利影响 破伤风 加药 梅德林 脑膜炎球菌疫苗 疾病 循证医学 疫苗效力 安慰剂对照研究 儿科 2019年冠状病毒病(COVID-19) 大流行 抗体反应
作者
Nicole M. Chase
出处
期刊:Allergy and Asthma Proceedings [OceanSide Publications, Inc]
卷期号:47 (2): 85-91 被引量:1
标识
DOI:10.2500/aap.2026.47.260001
摘要

Background: Biologics that target type 2 inflammation have transformed the management of atopic diseases, but questions remain with regard to vaccine administration in these patients. Current product labeling recommends caution with vaccine administration in patients taking these medications, particularly live-attenuated vaccines, despite limited evidence of actual risk. Objective: The objective was to review clinical concerns and available evidence, and to provide practical recommendations for vaccination in patients receiving biologics for atopic diseases, with a focus on dupilumab. Methods: A comprehensive PubMed/MEDLINE literature search was conducted to identify relevant studies and clinical guidance with regard to vaccination strategies in patients receiving biologic therapy. The primary search terms included the following: “biologic therapy” or “biologic therapy” or “monoclonal antibodies” combined with “vaccination” or “immunization” or “vaccine response” or “live vaccines” or “inactivated vaccines.” Priority was given to randomized controlled trials, large observational studies, and registry data published within the past 10 years. Results: For non-live vaccines, evidence supports safety and efficacy, although results of some studies suggest moderately reduced responses. A randomized controlled trial found comparable antibody responses between dupilumab and placebo groups for tetanus (83.3% versus 83.7%) and meningococcal vaccines (86.7% versus 87.0%). Coronavirus disease 2019 (COVID-19) vaccine studies show mixed results, with some reporting lower antibody levels and neutralization capacity in patients on biologics. For live-attenuated vaccines, emerging evidence challenges traditional prohibitions. Conclusion: Current evidence supports the safety and efficacy of non-live vaccines in patients receiving biologics for atopic diseases, although responses may be moderately reduced. Analysis of emerging data suggests certain live-attenuated vaccines may be safer than previously thought, particularly in pediatric patients on dupilumab. Vaccination decisions should be individualized based on risk-benefit assessment. Further research is needed to establish definitive guidelines, particularly for live vaccines and long-term immunity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zzh发布了新的文献求助10
刚刚
1秒前
研友_bZzJqZ发布了新的文献求助20
2秒前
橘络完成签到 ,获得积分10
2秒前
糖豆完成签到 ,获得积分10
3秒前
一幕清寒完成签到,获得积分20
5秒前
科研通AI65的应助被健壮的尔烟采纳,获得10
5秒前
脑洞疼的应助被zzh采纳,获得10
6秒前
7秒前
李子敬完成签到,获得积分10
9秒前
12秒前
13秒前
王聪关注了科研通微信公众号
13秒前
hcg完成签到,获得积分10
13秒前
bohe完成签到 ,获得积分10
15秒前
可爱的函函的应助被阿腾采纳,获得10
16秒前
摇摇晃晃完成签到 ,获得积分10
17秒前
17秒前
17秒前
畅销款发布了新的文献求助10
18秒前
18秒前
无奈的绾绾完成签到,获得积分10
18秒前
哈哈完成签到,获得积分10
19秒前
manh123发布了新的文献求助10
19秒前
海拾月发布了新的文献求助10
20秒前
lucky完成签到 ,获得积分10
22秒前
木瓜完成签到 ,获得积分10
22秒前
23秒前
23秒前
王聪发布了新的文献求助10
24秒前
杏仁核操纵子完成签到 ,获得积分10
25秒前
123y完成签到,获得积分10
25秒前
万重山完成签到 ,获得积分10
26秒前
科研废柴完成签到 ,获得积分10
28秒前
29秒前
阿腾发布了新的文献求助10
29秒前
baishier完成签到,获得积分10
31秒前
Weiding完成签到,获得积分10
31秒前
lior完成签到,获得积分10
32秒前
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179501
求助须知:如何正确求助?哪些是违规求助? 9569885
关于积分的说明 21807255
捐赠科研通 7774973
什么是DOI,文献DOI怎么找? 3433066
关于科研通互助平台的介绍 2556999
邀请新用户注册赠送积分活动 2478741